Prudentia Sciences announced it raised $20 million in Series A financing to expand its AI-native due diligence platform for life sciences dealmaking, aiming to help pharmaceutical companies, biotechs, and financial institutions evaluate therapeutic assets faster and with more rigor.
The round was led by McKesson Ventures with participation from SignalFire. Existing investors Iaso Ventures, Virtue, and GV also participated, bringing Prudentia’s total funding to $27 million following a $7 million seed round in 2024, the company said. Terms were not disclosed.
Prudentia said its platform synthesizes complex clinical and scientific signals into actionable insights to improve deal throughput and support acquisition, licensing, and investment decisions for business development, investing, and diligence teams. The company emphasized a human-in-the-loop model designed to support collaboration among buyers, sellers, and intermediaries within a secure and compliant workflow, while maintaining fully explainable AI outputs.
Prudentia said it will use the new funding to expand product capabilities, deepen intelligence for both technical and non-technical diligence, and scale commercial operations, including growth into Asia-Pacific and Europe.
KEY QUOTES:
“Prudentia is modernizing the way life sciences organizations harness data to evaluate assets and proactively manage risk. Their AI-native platform accelerates scientific due diligence with real-time insights, seamless integration, and intelligent automation – transforming a traditionally fragmented process into a connected, agile, and future-ready workflow.”
Dave Schulte, President, McKesson Ventures
“Life sciences dealmaking is inherently complex and time-intensive, with substantial capital and scientific innovation at stake. Biotechs struggle to present their assets with clarity and rigor, while pharma teams are forced to balance speed with thorough diligence. Without an intelligent platform to bridge this gap, diligence remains fragmented and high-risk. Prudentia collapses the distance between technical data and strategic conviction, enabling teams to make confident go-or-no-go decisions in a fraction of the time.”
Sadiqa Mahmood, Founder and CEO, Prudentia Sciences
